CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
A replay of the call will be available for one year and can be accessed via NASHVILLE, Tenn., July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024.
2024年7月30日田納西州納什維爾——專業藥品公司坎伯蘭藥業（納斯達克股票代碼：CPIX）今天宣佈，將於2024年8月6日星期二收盤後發佈2024年第二季度業績並提供公司更新。
A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at
將於美國東部時間8月6日下午4:30舉行電話會議，討論業績結果。請在以下網址註冊參加電話會議：
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
註冊後，與會者可以通過撥打支持的電話號碼並輸入個人識別碼號碼接入會議。或者，他們可以選擇“呼叫我”選項，在會議開始時自動由系統呼叫他們。
A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting .
電話會議錄音將保留一年，並可通過坎伯蘭藥業的網站或訪問鏈接進行獲取。
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
坎伯蘭藥業是一家專注於提供改善患者護理的獨特產品的專業藥品公司。公司開發、收購和銷售醫院急性護理、胃腸病和腫瘤市場領域的產品。
The company's portfolio of FDA-approved brands includes:
公司的FDA批准品牌包括：
- Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
- Sancuso (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
- 乙酰半胱氨酸針劑（Acetadote），用於治療對乙酰氨基酚中毒；
- 注射用布洛芬(Caldolor)，用於治療疼痛和發燒；
- 口服輕瀉劑盧通露司（Kristalose），用於治療便秘；
- 奧美拉唑，克拉黴素，阿莫西林套裝（Omeclamox-Pak），用於治療幽門螺桿菌感染和相關的十二指腸潰瘍病；
- 格拉司瓊（Sancuso），透皮給藥系統，用於預防接受某些化療治療的患者的噁心和嘔吐；
- 康維普坦（Vaprisol）針劑，用於提高住院患者中的保健和高容量低鈉血癥的血清鈉水平；
- 特拉凡芳（Vibativ）針劑，用於治療包括醫院獲得性和呼吸機相關性細菌性肺炎以及複雜的皮膚和皮膚結構感染在內的某些嚴重細菌感染。
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis. Additionally, Cumberland recently received FDA clearance to proceed directly to a Phase II study for patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease.
該公司還展開了一系列第二期臨床項目，評估其伊莎替羅班產品候選人在肌萎縮性侯謝氏肌肉萎縮症和全身性硬皮病患者中的心肌病的治療。此外，坎伯蘭最近獲得FDA的審批，直接進行了關於原發性肺纖維化患者的第二期研究，這是逐漸進展的間質性肺病最常見的形式。
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website at .
有關坎伯蘭已批准的產品的更多信息（包括完整的處方信息），請訪問公司網站上鍊接到各個產品網站的鏈接： .
SOURCE Cumberland Pharmaceuticals
參考來源：坎伯蘭藥業
譯文內容由第三人軟體翻譯。
